Levetiracetam Solution
Product Images NDC 72205-037

8 FDA label images from Novadoz Pharmaceuticals Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 72205-037). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle-label (Bottle Label)

Bottle-label (Bottle Label)
Label for Levetiracetam Oral Solution USP, 100 mg/mL, in a 16 fl oz (473 mL) container. The label includes storage instructions, a warning to keep out of reach of children, and pharmacist dispensing instructions. Distributed by Novadoz Pharmaceuticals LLC and manufactured by MSN Pharmaceuticals Inc, Piscataway, NJ. Includes the NDC 72205-037-72 and a barcode.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A bar chart comparing the percentage of patients across three groups: Placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). The y-axis shows the percentage of patients from 0% to 45%. The chart visually illustrates higher patient percentages in the Levetiracetam groups compared to placebo.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A bar graph showing the percentage of patients in three groups: Placebo with 6.3%, Levetiracetam 1000 mg/day with 20.8%, and Levetiracetam 2000 mg/day with 35.2%. The y-axis represents the percentage of patients, and the x-axis labels each group with patient counts (N). Asterisks indicate significance in the Levetiracetam groups.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
Bar chart comparing the percentage of patients responding to placebo versus Levetiracetam 3000 mg/day. The Y-axis shows the percentage of patients from 0% to 45%. The placebo group (N=104) has a response rate of 14.4%, while the Levetiracetam group (N=180) shows a higher response rate of 39.4%.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A bar chart comparing the percentage of patients between two groups: Placebo (N=97) and Levetiracetam (N=101). The y-axis represents the percentage of patients. The Placebo group shows 19.6%, while the Levetiracetam group shows a higher value of 44.6%. This chart illustrates a patient outcome comparison involving levetiracetam.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A bar chart comparing the percentage of patients between two groups: Placebo (N=51) at 19.6% and Levetiracetam (N=58) at 43.1%. The vertical axis represents the percentage of patients, ranging from 0% to 45%. The chart highlights a higher percentage in the Levetiracetam group.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
A bar graph comparing the percentage of patients for Placebo (N=84) and Levetiracetam (N=79). The y-axis shows the percentage of patients from 0% to 100%. The bar for Placebo shows 45.2%, while the bar for Levetiracetam shows 72.2%, indicating a higher percentage in the Levetiracetam group.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of levetiracetam, showing its molecular framework including a pyrrolidone ring, a methylpentanamide side chain, and functional groups characteristic to the molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.